MedTrace Logo

Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

NCT00055198 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2017-06-14

No results posted yet for this study

Summary

The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.

Conditions

  • Gram-Positive Bacterial Infections

Interventions

DRUG

daptomycin

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-19
Primary Completion
2004-01-26
Completion
2004-01-26

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055198 on ClinicalTrials.gov